An Open Label study to examine the effects of DAS181 administered by Dry Powder Inhaler (DPI) or Nebulized formulation in Immunocompromised subjects with Parainfluenza (PIV) Infection
|Effective start/end date||8/13/13 → 12/31/20|
- ANSUN BIOPHARMA, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.